Company intelligence / Profile preview

Anjarium Biosciences AG

Schlieren, Zurich Canton, Switzerlandanjarium.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

Anjarium Biosciences has developed a versatile non‑viral gene therapy platform combining proprietary DNA vectors with hybrid nanoparticle/exosome delivery systems. The approach aims to overcome limitations of viral vector therapies by enabling larger payloads, reduced immunogenicity, enhanced targeting, and potential for repeat dosing. As of its $61M Series A financing in late 2021, the company was advancing several preclinical programs toward clinical development but had not yet reported human data.[3][5]

Modalities: Non-viral gene therapies[3][7][8]DNA-based gene vectors[3][6][7]Nanoparticle delivery (natural and synthetic)[3][5][6]Exosome-based therapeutics[4]
Industry: Biotech

Partnerships

No major pharma partnerships announced as of latest updates; significant investors include Pfizer Ventures which may indicate strategic collaboration potential.[8]

Beyond the preview

Go deeper on Anjarium Biosciences AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anjarium Biosciences AG.

Explore the full profile